0
0
The Bill & Melinda Gates Foundation, in collaboration with the Pan American Health Organization (PAHO), is actively pursuing strategies to make highly effective but expensive weight-loss drugs more affordable and accessible in lower-income countries, Reuters reports on October 10, 2025. These medications, including Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, which are usually distributed in wealthier nations at monthly costs of several hundred dollars, have shown promise in treating obesity and related chronic conditions such as diabetes and cardiovascular diseases.
Key findings and developments
Worldwide, obesity affects nearly one billion people, with approximately 70% of those residing in low- and middle-income countries that frequently face challenges in affording treatment options. Bill Gates indicated that his foundation plans to take successful drugs from affluent nations and work on reducing their prices drastically to reach a global population. The Gates Foundation has previous experience in this area, having partnered with Indian manufacturer Hetero to provide affordable HIV prevention medications priced at around $40 annually.
Semaglutide, the active component in Wegovy, is set to lose patent protection from 2026 in major low-cost generic drug manufacturing countries such as India and China. This patent expiry opens the door for generic production, which could substantially lower prices and expand access. The foundation is considering supporting clinical trials to understand how these drugs affect diverse populations, data essential for broad regulatory approval and wider use.
Expert perspectives
Dr. Jarbas Barbosa, Director of PAHO, explained that his organization manages a fund which helps negotiate lower prices through bulk purchasing for its 35 member states. PAHO is also preparing guidelines on safe and effective use of these medicines and intends to collaborate with drug manufacturers and generic producers to streamline regulatory approval processes collectively for member countries.
Obesity and public health context
The World Health Organization warns that the global economic burden of obesity and overweight could reach $3 trillion by 2030 if no effective interventions are implemented. Obesity markedly increases the risk of chronic diseases, which in turn elevate healthcare expenditures and reduce quality of life.
Innovations like GLP-1 receptor agonists (the drug class that includes Wegovy and Mounjaro) work by mimicking natural hormones that regulate appetite and blood sugar levels, aiding patients in weight reduction and improved metabolic health.
Implications for public health and practical considerations
Making these medications affordable and available in low-income countries could dramatically change the obesity treatment landscape, which is currently limited by cost and accessibility disparities. For the general public, these developments hint at an expanding arsenal of tools to manage obesity, supplementing lifestyle interventions.
Limitations and balanced viewpoints
Despite the excitement, challenges remain, including ensuring these drugs’ affordability without compromising quality, understanding long-term safety across diverse populations, and integrating pharmacologic treatment with public health efforts such as diet and exercise promotion. Additionally, while the Gates Foundation’s arrival in obesity care marks an important commitment, obesity is not currently the primary health priority in many of the countries where it operates, reflecting the complex balancing of global health needs.
Medical Disclaimer:
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
